Cerus: 3 Key Takeaways for Long-Term Investors

Cerus announced positive Phase III trial results for red blood cell pathogen reduction technology, a major market expansion opportunity. The company is shifting to higher-margin kit distribution for its fibrinogen complex product and achieved positive operating cash flow of $3 million. A partnership with Blood Centers of America is accelerating North American adoption, positioning the company toward GAAP profitability.